Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: psilocybin-based therapeutics - Nova Mentis Life Science/Pilz Bioscience

Next Previous
Search
Drug Profile

Research programme: psilocybin-based therapeutics - Nova Mentis Life Science/Pilz Bioscience

Alternative Names: Aeruginascin; Psilocybin-based therapeutics - Nova Mentis Life Science/Pilz Bioscience

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roma Tre University
  • Developer Nova Mentis Life Science
  • Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
  • Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pervasive child development disorders

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for preclinical development in Pervasive-child-development-disorders in Canada
  • 09 Nov 2021 Nova Mentis Life Science files patent protection for Genetic neuroinflammatory disease describing diagnostic/therapeutic combination of mRNA molecules for Fragile X syndrome and Pervasive child development disorders in November 2021
  • 29 Dec 2020 Preclinical trials in Pervasive child development disorders in Canada (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top